Celiac disease: Autoimmunity in response to food antigen

Stamnæs, Jorunn; Sollid, Ludvig M.

doi:10.1016/j.smim.2015.11.001

Cited by 123 publications

(115 citation statements)

References 141 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…The gliadin peptides that promote CD generally harbor one or more epitopes capable of binding to human T cells212223. Such epitopes are also present in HMW-GSs and LMW-GSs but in a reduced amount510.…”

mentioning

confidence: 99%

Genome-wide analysis of complex wheat gliadins, the dominant carriers of celiac disease epitopes

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Gliadins, specified by six compound chromosomal loci (Gli-A1/B1/D1 and Gli-A2/B2/D2) in hexaploid bread wheat, are the dominant carriers of celiac disease (CD) epitopes. Because of their complexity, genome-wide characterization of gliadins is a strong challenge. Here, we approached this challenge by combining transcriptomic, proteomic and bioinformatic investigations. Through third-generation RNA sequencing, full-length transcripts were identified for 52 gliadin genes in the bread wheat cultivar Xiaoyan 81. Of them, 42 were active and predicted to encode 25 α-, 11 γ-, one δ- and five ω-gliadins. Comparative proteomic analysis between Xiaoyan 81 and six newly-developed mutants each lacking one Gli locus indicated the accumulation of 38 gliadins in the mature grains. A novel group of α-gliadins (the CSTT group) was recognized to contain very few or no CD epitopes. The δ-gliadins identified here or previously did not carry CD epitopes. Finally, the mutant lacking Gli-D2 showed significant reductions in the most celiac-toxic α-gliadins and derivative CD epitopes. The insights and resources generated here should aid further studies on gliadin functions in CD and the breeding of healthier wheat.

show abstract

mentioning

confidence: 99%

Genome-wide analysis of complex wheat gliadins, the dominant carriers of celiac disease epitopes

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These topics opened also the pathway to consider Tgase2 as a target for therapy and several kinds of inhibitors have been developed, spanning from competitive substrates, up to reversible and irreversible blockers of the active site, to GTP mimics and to stabilizers of conformational states. These aspects have been extensively reviewed (Lai et al 2008;Badarau et al 2015;Keillor et al 2015) along with the effects of the antibodies on the enzyme in a number of autoimmune diseases, notably in celiac disease (Stamnaes and Sollid 2015). Of extreme interest are also the observations about the role of Tgase in antineoplastic therapies because of its intervention in the drug stimulated apoptosis (Budillon et al 2013).…”

Section: The Physiology: Integrated Responses Of Cells and Tissuesmentioning

confidence: 99%

Transglutaminase 2, a double face enzyme

2017

View full text Add to dashboard Cite

“…Many patients will have anti-tTG and anti-endomysial antibodies and have marked autoinflammation and many children have growth failure, cachexia, abdominal pain (Zucchini et al, 2016). As discussed in review by Stamnaes and Sollid (2015), CD is complex and the interaction of specific T cells and B cells directed against modified protein/peptides of gluten and of the tissues of the human are not directly tied to autoimmune disease, but the evidence suggests that it becomes established as an autoimmune disease. 6.…”

Section: Informationmentioning

confidence: 99%

Outcome of the public consultation on the draft guidance on allergenicity assessment of genetically modified plants

2017

EFSA Supporting Publications

View full text Add to dashboard Cite

The European Food Safety Authority (EFSA) carried out a public consultation to collect input from the scientific community and all interested parties on the draft guidance on allergenicity assessment of genetically modified plants. The draft guidance document was prepared by the Allergenicity Working Group of the EFSA Panel on Genetically Modified Organisms (GMO Panel) and endorsed by the Panel for public consultation at its plenary meeting on 26 July 2016. EFSA received approximately 200 comments on the draft guidance from 25 interested parties. As part of EFSA's public consultation, an EFSA workshop at an initial stage of the process as well as an EFSA info session meeting were held in Brussels on 17 June 2015 and in Parma on 23 rd November 2016, respectively. In addition, a pilot "Focus group" project involving several stakeholder groups closely followed the development of the document during its entire lifetime. The current report summarises the outcome of the public consultation, and includes a brief description of the comments received and how the comments were addressed. EFSA and its GMO Panel wish to thank all stakeholders and the general public for their contributions. The GMO Panel prepared an updated version of the guidance taking into account the comments received. The guidance document was adopted at the GMO Plenary meeting on 18 May 2017, and is published in the EFSA Journal.

show abstract

Celiac disease: Autoimmunity in response to food antigen

Cited by 123 publications

References 141 publications

Genome-wide analysis of complex wheat gliadins, the dominant carriers of celiac disease epitopes

Genome-wide analysis of complex wheat gliadins, the dominant carriers of celiac disease epitopes

Transglutaminase 2, a double face enzyme

Outcome of the public consultation on the draft guidance on allergenicity assessment of genetically modified plants

Contact Info

Product

Resources

About